White Paper
Jun 16, 2025
New Product Alert – Ruxolitinib Phosphate
May 26, 2025
Product Alert - Rimegepant
May 5, 2025
Product Alert – Mavacamten
Apr 24, 2025
New Product Alert - Ripretinib
Mar 4, 2025
Product Alert - Lumateperone Tosylate
Feb 12, 2025
New Product Alert - Ribociclib
Jan 10, 2025
New Product Alert - Ruxolitinib & Salts
Dec 18, 2024
Tech Sheet On Nilotinib Hydrochloride
Oct 18, 2024
Tech Sheet – Mirabegron API
Sep 25, 2024
Tech sheet – Apremilast
May 31, 2024
Product Alert - Relugolix API
May 31, 2024
Tech Sheet on Enzalutamide Premix
May 31, 2024
Product Alert – Mirogabalin Besylate
Apr 22, 2024
Product Alert – Vonoprazan Fumarate
Feb 21, 2024
Tech Sheet - Cabozantinib (S)-malate API
Dec 7, 2023
Product Alert – Deucravacitinib API
Dec 4, 2023
Substantially Pure Carfilzomib Amorphous for Generic Launch
Nov 6, 2023
Product Alert – Mavacamten API
Jul 21, 2023
White Paper on Sugammadex API
Jul 21, 2023
Tech Sheet on Pregabalin API
Mar 20, 2023
Product Alert – Niraparib API
Mar 13, 2023
Product Alert – Tucatinib API
Mar 6, 2023
Product Alert – Pazopanib API
Jan 20, 2023
Tech Sheet on Midostaurin API
Jan 9, 2023
Tech Sheet on Tofacitinib Citrate
Nov 4, 2022
Tech Sheet on Dutasteride
Oct 14, 2022
Tech Sheet on Linagliptin
Oct 12, 2022
Tech Sheet on Voriconazole
Aug 4, 2022
Addressing the presence of mutagenic Azido impurities in Sartan APIs
Aug 3, 2022
Co-Crystal and Customized Particle Size for Early Launch Opportunity of Siponimod API
Jul 29, 2022
New Product Alert – Lumateperone Tosylate API
Jun 15, 2022
Tech sheet: Dr. Reddy's Bempedoic Acid API Offerings
Apr 4, 2022
Tech sheet: Dr. Reddy's Olaparib API Offerings
Mar 30, 2022
Tech sheet: Dr. Reddy's Enzalutamide API Offerings
Feb 22, 2022
Tech Sheet - Dr. Reddy’s Eribulin Mesylate API offerings
Feb 9, 2022
Tech Sheet – Dr. Reddy’s Fexofenadine API offerings
Feb 4, 2022
Tech Sheet - Dr. Reddy’s Azacitidine API offerings
Feb 4, 2022
Tech Sheet - Dr. Reddy’s Ramipril API offerings
Dec 17, 2021
Tech Sheet - Dr. Reddy’s Gemcitabine API offerings
Dec 2, 2021
Tech Sheet: Dr. Reddy’s Abiraterone Acetate API offerings
Oct 8, 2021
瑞德西韦（Remdesivir）系由瑞迪博士（Dr.Reddy’s）在吉利德（Gilead）许可下研发：
Aug 17, 2021
白皮书： 瑞迪博士的2 DG - 一种对住院的新冠病毒病患者来极具前景的治疗方法
Aug 17, 2021
技术表： 瑞迪博士的乐伐替尼（Lenvatinib）原料药产品
Jun 18, 2021
罗沙司他（ROXADUSTAT）- 多管齐下的发展战略
May 19, 2021
瑞迪博士的阿普斯特片（Apremilast）原料药和成品配方产品。
May 3, 2021
瑞迪博士的福沙吡坦（Fosaprepitant）原料药产品
Apr 15, 2021
阿哌沙班（Apixaban）原料药 - 易压缩颗粒和成品剂型
Apr 6, 2021
阿帕鲁胺（Apalutamide）原料药 - 对仿制药公司极具吸引力的NCE-1机遇
Apr 6, 2021
胶体铁络合物（Colloidal Iron Complex）配方 - 认识和发展流程
Feb 9, 2021
瑞迪博士的利伐沙班（Rivaroxaban）： 完整的原料药和成品配方产品
Jan 22, 2021
瑞迪博士提供的阿尔法型和非晶型（Mirabegron） 原料药
Jan 13, 2021
帕博西尼（Palbociclib） - 新流程开发方法如何提供知识产权优势
Nov 25, 2020
瑞迪博士的恶拉戈利（Elagolix ）原料药提供了全面的质量源于设计方法
Jul 20, 2020
沙库必曲/缬沙坦（Sacubitril/Valsartan）（LCZ696） - 通过创新的原料药产品带来另一个优势
Jul 10, 2020
瑞迪博士流动化学专家在《今日化学》（Chemistry Today）小组讨论会上分享了他们的观点
May 20, 2020
进一步了解瑞迪博士如何满足雷诺嗪（Ranolazine）中基因毒性杂质的严格监管要求
May 7, 2020
法莫替丁（Famotidine）和尼扎替丁（Nizatidine）原料药： 受控的亚硝基二甲胺（NDMA），定制的颗粒分布，安全的供应链
Oct 17, 2019
满足沙坦（Sartan）原料药生产的新法规要求
Articles
Jul 25, 2025
Development of Niche Products at Dr. Reddys API
Apr 2, 2025
Harnessing India's New Drug Development Capabilities for Global Impact
Mar 11, 2025
The Impact of Global Regulations on the Active Pharmaceutical Ingredient Industry
Mar 3, 2025
The Importance of Supply Chain Management and Dr. Reddy’s Excellence
Feb 10, 2025
Current Landscape of Cancer Treatment in India and Dr. Reddy's Role in Enhancing Care
Jan 12, 2025
Global Development Strategy for Generic Formulations and APIs
Jan 6, 2025
APIs for Emerging Markets: Opportunities and Challenges
Dec 15, 2024
Formulation Strategies and Pharmaceutical Analysis for Anti-diabetic APIs
Dec 2, 2024
API Quality Control Technologies & Strategies: Current Advancements for Benefiting Pharma Companies
Oct 9, 2024
A year of growth & Sustainability
Aug 30, 2024
Understanding Nitrosamines and GTI Issues in APIs: A Comprehensive Overview with Dr. Reddy's Perspective
Aug 28, 2024
Innovative Approaches to API Production in 2024: Shaping the Future of Pharma Companies
Jul 30, 2024
Continuous Manufacturing Process and Its Impact on Pharma Manufacturing
Jun 28, 2024
A Comparative Study on Naproxen Formulations
Jun 18, 2024
An effective strategy for the development of docetaxel
May 22, 2024
Preformulation Studies for Generic Omeprazole
May 15, 2024
A comparative study on enzalutamide Formulations
Apr 30, 2024
Navigating the Heart of Pharmaceuticals: An In-Depth Exploration of Active Pharmaceutical Ingredient Manufacturing for Essential Medicines
Apr 1, 2024
Presence of Organic Impurities in active pharmaceutical ingredients: An Overview
Mar 30, 2024
Strategies and Technologies for Enhancing Cost-Effectiveness in Active Pharmaceutical Ingredient (API) Production
Mar 29, 2024
Effective Formulation Development Strategies for Poorly Soluble Active Pharmaceutical Ingredients (APIs)
Feb 29, 2024
Ensuring Drug Safety: Comprehensive Analysis of Active Pharmaceutical Ingredient Lists
Feb 28, 2024
Unravelling the Science: Pharmaceutical Compositions and Process of Levetiracetam API
Nov 16, 2023
Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Refractory Chronic Lymphocytic Leukemia
Aug 10, 2023
Demonstrating Equivalence of Generic Glatiramer Acetate: Ensuring Quality and Safety
May 25, 2023
Streamlining the Process: Preparing a Pharmaceutical Composition of Fosaprepitant API
Dec 30, 2022
Steps taken by Dr. Reddy's Laboratories in controlling the environmental risks and safety management in the manufacturing of APIs
Dec 7, 2022
Meeting the New Regulatory Requirements and Controlling of Nitrosamine Impurities in Sartan API Production
Sep 14, 2022
Effective Formulation Development Strategies for Poorly Soluble Active Pharmaceutical Ingredients
Sep 13, 2022
Reshaping the Pharmaceutical API Industry with Digital Transformation
Aug 2, 2022
7 Ways how Active Pharmaceutical Ingredients (APIs) Enable Indian Pharmaceutical Companies to Grow
Aug 2, 2022
How is the Indian Pharmaceutical industry gearing up for 2022-2023?
Apr 14, 2022
Impact of COVID-19 on Indian HPAPI industry
Apr 14, 2022
The synthesis of active pharmaceutical ingredients (APIs) using continuous flow chemistry
Sep 14, 2021
瑞迪博士的61种原料药均采用巴西卫生监督局（ANVISA）认证的良好生产规范（GMP） 药品成分
Jul 7, 2021
产品生命周期管理：萘普生（Naproxen）原料药和配方
May 27, 2021
了解原料药： 拉马尼·苏萨拉 （Ramani Susarla）博士的制药原料展览会（CPHI）演讲
Mar 31, 2021
EMA Nitrosamine Guidance – Deadline March 31, 2021
Nov 26, 2020
2021年患者为中心和供应链安全 - 拉杰什·萨达南丹 （Rajesh Sadanandan）就2021年世界医药原料展（CPhI）制药趋势发表了讲话
Nov 19, 2020
瑞迪博士关于在单颗粒水平上同时进行自动图像分析和拉曼光谱的研究出版物
Sep 14, 2020
范式转变将持续 - 索里•古德拉瓦莱蒂（Sauri Gudlavalleti）与CME经理谈论新冠病毒病应对措施
Sep 7, 2020
充满挑战与机遇的一年 - 制药服务和活性成分（PSAI）全球主管迪帕克•萨普拉接受了《药物厂商》（The Medicine Maker）的采访
Sep 2, 2020
新冠病毒病和原料药采购的下一步是什么？
Aug 25, 2020
印度医疗改革提供了蓬勃发展的医药市场机会： 采访迪帕克·萨普拉（Deepak Sapra）
Jun 1, 2020
瑞迪博士正在通过大规模生产能力和后向一体化来改善普瑞巴林（Pregabalin）原料药的供应链绩效
Dec 1, 2019
Enhancing Supply Chain Security for Levetiracetam API
News
Aug 5, 2025
Tentative Approval for Generic Lumateperone capsules
Jul 10, 2025
CDP Recognition
Jun 24, 2025
Dr. Reddys API team at CPHI China 2025
Apr 9, 2025
CPHI Japan 2025 - Exhibitor showcase session by Nirav K Shah, Vice President, Head API, North Asia
Apr 9, 2025
Dr. Reddys API team at CPHI Japan 2025
Mar 17, 2025
Dr. Reddys API team at DCAT 2025
Feb 25, 2025
Dr. Reddy’s Wins Big at “Express Pharma Excellence Awards 2025”
Dec 18, 2024
Celebrating Creativity and Festivity: API Calendar Launch 2025!
Nov 29, 2024
Dr. Reddy’s wins CPHI & PMEC India Award for Excellence in Ancillary Pharma Services - Supply Chain & Logistics for enhancing customer experience
Nov 29, 2024
Dr. Reddy’s wins CPHI & PMEC India Award for developing a continuous API manufacturing process.
Nov 29, 2024
Dr. Reddy's API team at CPHI India 2024
Oct 13, 2024
Dr. Reddy's API team at CPHI Milan 2024
Sep 27, 2024
Gunjan Singh at the CPHI Webinar: The Changing Dynamics of Global API Manufacturing
Sep 27, 2024
Karun Gaur at CPHI Milan: Panel Discussion on Pharma Manufacturing in Emerging Markets - Moving Towards Localization in Africa
Jul 8, 2024
Deepak Sapra's Visionary Keynote on Healthcare Innovation at DXEM 2024
May 8, 2024
Dr. Reddy's AI Day: Igniting the Future of Healthcare with Innovation
Apr 25, 2024
USP recognized Dr. Reddy’s with a crystal award for significant contribution towards “New and modernized monograph submissions”
Apr 22, 2024
Dr. Reddy’s API at CPHI Japan 2024
Apr 5, 2024
Dr. Reddys Strategic collaboration with Industrial Promotion Services (IPS) to support the East African Combined Pharmaceutical Center (EACPC) in Kenya
Jan 2, 2024
Dr. Reddy's API Calendar 2024 Unveiling: A Magical Celebration of Creativity, Joy, and Togetherness with Our Global Team's Talented Young Artists
Dec 5, 2023
Dr. Reddy's Pioneers Pharma Advancements Through Strategic Partnerships and Innovation: A Glimpse into Vision 2030: Growth Trajectory and Opportunities for Indian Pharma
Nov 30, 2023
Dr. Reddy’s at CPHI India 2023
Nov 23, 2023
Dr. Reddy’s at 5th CII LIFE SCIENCES SUMMIT 2023 - Making India a Global Pharma and Lifesciences Innovation Hub
Nov 11, 2023
Asia-Pacific Climate Leader Award
Nov 10, 2023
Dr. Reddy’s Achieves AEO-T3 Certification, Elevating Global Trade Facilitation
Oct 28, 2023
Dr. Reddy’s API at CPHI Worldwide 2023
Aug 20, 2023
Dr. Reddys at G20 Summit 2023
Jun 25, 2023
Dr. Reddy’s API at CPHI China 2023
Mar 15, 2023
Being Prepared for What's Next and a Shared Purpose of Serving Patients Whatever it Takes
Feb 15, 2023
Dr. Reddy’s included in Bloomberg Gender-Equality Index for the 6th year in a row and S&P Global’s Sustainability Yearbook for the 3rd year
Jan 5, 2023
Dr. Reddy's API calendar 2023
Nov 11, 2022
COVID-19: Prime Minister of India Meets Pharma leaders
Nov 6, 2022
Addressing NDMAs in Pharmaceuticals
Nov 5, 2022
Dr.Reddy's at CPHI India 2022 Panel Discussion
Nov 4, 2022
Dr. Reddy’s API received the excellence in API – Technical Documentation award at Aché Laboratórios Parcerias para a Excelência (Partnerships – Excellence) event!
Oct 6, 2022
Dr. Reddy's API participated in the 2022 Pharmaceutical Industry and Regulators Symposium at ANVISA
Sep 27, 2022
Expert statement by Srividya Ramakrishnan, Head, API process engineering, Dr. Reddy’s Laboratories. Published in CHE Manager
Sep 25, 2022
Dr. Reddys attended ACHEMA 2022 Conference
Nov 11, 2021
Dr. Reddy’s API team is a 2021 winner in – API Supplier of the year at Global generics & Biosimilars awards
Nov 11, 2021
The winner of the Corporate social responsibility (CSR) Initiative of the year at Global generics & Biosimilars Awards
Oct 7, 2021
2021年美国制造业最佳印度公司的获胜者
Oct 6, 2021
舒更葡糖钠原料药 - 巴西卫生监督局批准的原料药档案适当性函
May 27, 2021
迪帕克•萨普拉谈到了印度国防研究与发展组织的抗新冠病毒药物2DG
May 27, 2021
Dr.Reddy’s gearing up with Covid portfolio: Deepak Sapra, CEO of API & Services, speaks to India Today
Jan 21, 2021
2021年度制药行业最佳供应链团队
Nov 10, 2020
瑞迪博士实验室的阿尼尔•帕特尼 （Anil Patni）在《制造化学家》（Manufacturing Chemist）现场虚拟会上介绍了高效原料药（HPAPIs）
Nov 3, 2020
瑞迪博士实验室在2020年全球仿制药和生物仿制药奖（Global Generics & Biosimilars Awards）上获得“年度原料药供应商”奖
Oct 19, 2020
瑞迪博士在2020年世界医药原料展制药奖（CPhI Pharma Awards 2020）上获得了“卓越制药：可持续发展”类别的荣誉：
Oct 13, 2020
世界医药原料展制药节圆桌会议： 解决亚硝胺污染问题
Oct 5, 2020
瑞迪博士的实验室加入了科学基础目标计划（SBTi），制定了2030年的温室气体排放目标
Oct 5, 2020
世界医药原料展制药节专题讨论：跨境创新： 制药公司和创新者如何抗击新冠病毒病以及前进的道路。
Jul 1, 2020
瑞迪博士与富士胶片和Avigan®（法匹拉韦）全球响应援助机构（Global Response Aid）合作，Avigan®是一种潜在的新冠病毒病治疗药物
Apr 14, 2020
瑞迪博士关于新冠病毒病大流行的报告
Apr 1, 2020
《全球制药视野》上的一篇题为《亚硝胺污染：制药公司对其供应链的重新评估》的文章特别介绍了瑞迪博士。
Apr 1, 2020
左氧氟沙星半水合物（Levofloxacin Hemihydrate）获得欧洲药典适用性认证（CEP）
Mar 1, 2020
阿帕鲁胺的美国药物主文件 - 现已可用
Mar 1, 2020
瑞迪博士2018-19年可持续发展报告
Dec 1, 2019
瑞迪博士的原料药团队搬进其在中国的新办公室
Nov 1, 2019
瑞迪博士的实验室在2019年全球仿制药和生物仿制药奖上获得“年度原料药供应商”奖
Webinars
Updates
2020 - December
Dapagliflozin Propane Diol
Brazil DMF
2020 - December
Abiraterone Acetate
Brazil DMF
2020 - December
Sugammadex Sodium
China DMF
2020 - December
Lurasidone HCl
China DMF
2020 - December
Raloxifene HCl
China DMF
2020 - December
Apremilast (Form-B)
China DMF
2020 - December
Atorvastatin Calcium [Form-1] [ATN]
Korea DMF
2020 - December
Rabeprazole Sodium (Amorphous)
CEP Submitted
2020 - December
Pregabalin
Japan DMF
2020 - December
Famotidine
Japan DMF
2020 - December
Lenalidomide
USDMF
2020 - December
Clopidogrel Bisulfate
USDMF
2020 - December
Roxadustat
USDMF
2020 - December
Elagolix
USDMF
2020 - December
Atorvastatin Calcium Trihydrate [Form-1] [ATN]
Brazil DMF
2020 - December
Montelukast Sodium USP
Brazil DMF
2020 - December
Pregabalin
Brazil DMF
2020 - December
Capecitabine
Brazil DMF
2020 - November
Sitagliptin Phosphate (Anhydrous)
China DMF
2020 - November
Dutasteride (Form-II)
Canada DMF
2020 - November
Rabeprazole Sodium Hydrate (form-Y) RBL process
CEP Submitted
2020 - November
Clopidogrel Bisulphate [Form-I] (CIP)
Brazil DMF
2020 - October
Divalproex Sodium
Brazil DMF
2020 - October
Rivaroxaban
Brazil DMF
2020 - October
Mirabegron Amorphous
Brazil DMF
2020 - September
Losartan K
Brazil DMF
2020 - September
Ondansetron HCl
China DMF
2020 - September
Canagliflozin Hemihydrate
China DMF
2020 - September
Raloxifene HCl
Korea DMF
2020 - September
Escitalopram Oxalate
Korea DMF
2020 - September
Ticagrelor
CEP Submitted
2020 - September
Fexofenadine HCl ( form X)
Japan DMF
2020 - September
Midostaurin
USDMF
2020 - August
Keterolac Tromethamine
Brazil DMF
2020 - August
Ondansetron Hydrochloride
Brazil DMF
2020 - August
Sitagliptin Phosphate Anhydrous
Brazil DMF
2020 - August
Naratriptan Hydrochloride
Brazil DMF
2020 - August
Valsartan [micronized]
Brazil DMF
2020 - August
Pregabalin
China DMF
2020 - August
Tizanidine
CEP Submitted
2020 - July
Montelukast Sodium Ph.Eur.
Brazil DMF
2020 - July
Gemcitabine Hydrochloride
Brazil DMF
2020 - July
Sertraline HCl (SET4L)
Brazil DMF
2020 - July
Rivaraoxaban
CEP Submitted
2020 - June
Ticagrelor
Brazil DMF
2020 - June
Levetiracetam
Brazil DMF
2020 - June
Clopidogrel Bisulphate Form-1
Brazil DMF
2020 - June
Sugammadex Sodium
Brazil DMF
2020 - June
Sitagliptin HCl (CIP)
Korea DMF
2020 - June
Icatibant Acetate
Europe ASMF filed
2020 - June
Azacitidine
Japan DMF
2020 - June
Liraglutide
USDMF
2020 - May
Valsartan
Canada DMF
2020 - May
Esclicabazepine Acetate
Europe ASMF filed
2020 - May
Abiraterone acetate
Europe ASMF filed
2020 - April
Valsartan [Compacted]
Brazil DMF
2020 - April
Dasatinib SPG Solvate
Brazil DMF
2020 - April
Atorvastatin Calcium Trihydrate (Form-1)
Canada DMF
2021 - December
Moxifloxacin hydrochloride
Brazil DMF
2021 - December
Mirabegron [Alpha]
Brazil DMF
2021 - December
Sitagliptin Phosphate MH
Brazil DMF
2021 - November
Eribulin Mesylate
USDMF
2021 - November
Sacubitril/Valsartan
China DMF
2021 - November
Gemcitabine Hydrochloride
China DMF
2021 - November
Azacitidine
China DMF
2021 - November
Rivaroxaban (Ph.Eur)
Brazil DMF
2021 - November
Lenalidomide [Form-A]
CEP Submitted
2021 - October
Quetiapine Fumarate (Ph.Eur)
Brazil DMF
2021 - October
Quetiapine Fumarate (USP)
Brazil DMF
2021 - October
Rabeprazole Sodium (Form-Y)
Brazil DMF
2021 - October
Pioglitazone Hydrochloride
Japan DMF
2021 - October
Atorvastatin Calcium (Amorphous)
Brazil DMF
2021 - September
Enalaprilat
USDMF
2021 - September
Atorvastatin Calcium [Form-P]
Brazil DMF
2021 - September
Dabigatran Etexilate Mesilate [Form-2]
Brazil DMF
2021 - September
Dutasteride [Form-II]
Brazil DMF
2021 - September
Cinacalcet HCl
China DMF
2021 - September
Mirabegron (Alpha)
China DMF
2021 - August
Ibandronate Sodium Monohydrate [Form-B]
Brazil DMF
2021 - July
Edaravone
CEP Submitted
2021 - July
Ranolazine
CEP Submitted
2021 - July
Enzalutamide
Brazil DMF
2021 - July
Metoprolol Succinate FW
Brazil DMF
2021 - June
Lenvatinib mesylate (Form C)
USDMF
2021 - June
Dapagliflozin PG Solvate [Micronized]
Korea DMF
2021 - June
Clopidogrel Bisulphate [Form-II]
Korea DMF
2021 - June
Olanzapine [Form-I]
Korea DMF
2021 - June
Levofloxacin (USP) Hemihydrate
Korea DMF
2021 - June
Azacitidine
Brazil DMF
2021 - June
Pregabalin
Brazil DMF
2021 - June
Diluted Everolimus
Brazil DMF
2021 - June
Atorvastatin Calcium Trihydrate [Form-I] USP
Brazil DMF
2021 - June
Midostaurin - Crystalline Form II
Brazil DMF
2021 - May
Dimethyl Fumarate
EDMF filed
2021 - May
Olanzapine
Korea DMF
2021 - May
Ropinirole
CEP Submitted
2021 - May
Rivastigmine HT P-1
CEP Submitted
2021 - May
Esomeprazole Magnesium Trihydrate
CEP Submitted
2021 - May
Eribulin Fragment A
USDMF
2021 - April
Pregabalin
USDMF
2021 - March
Lenalidomide (LEU1)
Brazil DMF
2021 - March
Losartan Potassium
Japan DMF
2021 - March
Clopidogrel Bi-sulfate (Form-II)
Japan DMF
2021 - March
Amlodipine Besilate
China DMF
2021 - March
Abiraterone Acetate
Japan DMF
2021 - March
Naproxen Sodium
Brazil DMF
2021 - March
Naproxen
Brazil DMF
2021 - March
Sitagliptin Phosphate Ph.Eur (monohydrate)
CEP Submitted
2021 - March
Apalutamide (Amorphous)
USDMF
2021 - March
Finasteride (Form-I)
China DMF
2021 - March
Ondansetron base
Brazil DMF
2021 - March
Rabeprazole Sodium [Amorphous]
Japan DMF
2021 - March
Dabigatran Etexilate Mesylate
Korea DMF
2021 - March
Bendamustine Hydrochloride
Brazil DMF
2021 - March
Sitagliptin Phosphate Monohydrate USP
Brazil DMF
2021 - March
Rabeprazole Sodium [Amorphous]
China DMF
2021 - March
Pregabalin
China DMF
2021 - March
Fingolimod Hydrochloride
China DMF
2021 - March
Dapagliflozin (Amorphous)
China DMF
2021 - March
Olaparib
USDMF
2021 - March
Diroximel Fumarate
USDMF
2021 - March
Sitagliptin Phosphate Monohydrate USP
USDMF
2021 - March
Lurasidone HCl
Brazil DMF
2021 - March
Atorvastatin Calcium Trihydrate [Form-I] ATN process
China DMF
2021 - March
Rivaroxaban
Korea DMF
2021 - March
Pazopanib Hydrochloride
USDMF
2021 - March
Finasteride (Form-I)
Brazil DMF
2021 - February
Permethrin-25:75
CEP Submitted
2021 - February
Pregabalin
Korea DMF
2021 - February
Ondansetron Hydrochloride
Korea DMF
2021 - February
Sitagliptin Phosphate USP (monohydrate)
USDMF
2021 - February
Hydroxychloroquine Sulfate
USDMF
2021 - February
Favipiravir
USDMF
2021 - February
Levetiracetam
Korea DMF
2021 - February
Clopidogrel Bisulphate Form-2
CEP Submitted
2021 - January
Bendamustine HCl
Canada DMF
2021 - January
Fexofenadine Form-1
CEP Submitted
2021 - January
Mirabegron
Europe ASMF filed
2022 - December
Capecitabine
Japan DMF
2022 - December
Dabigatran Etexilate Mesylate
China DMF
2022 - December
Naproxen
China DMF
2022 - November
Ketorolac Tromethamine
China DMF
2022 - October
Linagliptin
EUDMF
2022 - October
Linagliptin
Brazil DMF
2022 - October
Dimethyl Fumarate
EUDMF
2022 - October
Nilotinib Hydrochloride Monohydrate
Brazil DMF
2022 - October
Levocetirizine Dihydrochloride
Brazil DMF
2022 - October
Clopidogrel Bisulphate (Form - II)
China DMF
2022 - September
Sitagliptin Phosphate Monohydrate
Korea DMF
2022 - September
Sumatriptan Succinate USP
USDMF
2022 - September
Atorvastatin Calcium Trihydrate (Form-1)
Brazil DMF
2022 - September
Dimethyl Fumarate
Brazil DMF
2022 - September
Atorvastatin Calcium Trihydrate (Form-1)
Japan DMF
2022 - September
Clopidogrel Bisulfate [Form-II]
EUDMF
2022 - August
Metoprolol Succinate
CEP Submitted
2022 - August
Clopidogrel Bisulfate [Form-I] CIP
Brazil DMF
2022 - August
Moxifloxacin Hydrochloride USP
Brazil DMF
2022 - August
Fexofenadine Hydrochloride
Korea DMF
2022 - August
Clopidogrel Bisulfate [Form-II]
CEP Submitted
2022 - July
Nilotinib Hydrochloride
USDMF
2022 - July
Tofacitinib Citrate
USDMF
2022 - July
Eribulin Mesylate
Canada DMF
2022 - July
Palbociclib [Form-A]
Brazil DMF
2022 - June
Bempedoic Acid
Brazil DMF
2022 - June
Lurasidone Hydrochloride
EUDMF
2022 - June
Eribulin Mesylate
EUDMF
2022 - May
Ticagrelor
Russia DMF
2022 - May
Escitalopram Oxalate
CEP Submitted
2022 - May
Sugammadex Sodium
Taiwan DMF
2022 - May
Sitagliptin Phosphate Monohydrate
CEP Submitted
2022 - April
Losartan Potassium
Japan DMF
2022 - March
Siponimod Hemifumarate
USDMF
2022 - March
Bempedoic Acid
USDMF
2022 - March
Risperidone [Form-1]
Brazil DMF
2022 - March
Sacubitril + Valsartan Crystalline
Brazil DMF
2022 - March
Ramipril
Brazil DMF
2022 - March
Levofloxacin Hemihydrate
Brazil DMF
2022 - March
Voriconozole
Brazil DMF
2022 - March
Apremilast [Amorphous]
Brazil DMF
2022 - March
Apremilast [Form-B]
Brazil DMF
2022 - March
Siponimod Hemifumarate
Brazil DMF
2022 - March
Metoprolol Succinate
China DMF
2022 - March
Dapagliflozin PG Solvate
China DMF
2022 - March
Pemetrexed Disodium Heptahydrate
China DMF
2022 - March
Clopidogrel Bisulphate [Form-1]
Japan DMF
2022 - March
Rivaroxaban
Japan DMF
2022 - March
Lenalidomide [Form-A]
Japan DMF
2022 - March
Naratriptan Hydrochloride
Japan DMF
2022 - March
Fingolimod Hydrochloride
CEP DMF Filed
2022 - March
Sugammadex Sodium
Canada DMF
2022 - March
Apremilast Form B
Korea DMF
2022 - March
Rabeprazole Sodium [Amorphous]
Korea DMF
2022 - March
Sumatriptan Succinate
Korea DMF
2022 - March
Enzalutamide
Korea DMF
2022 - March
Sacubitril/Valsartan
Korea DMF
2022 - March
Pioglitazone Hydrochloride
Korea DMF
2022 - March
Montelukast Sodium
Korea DMF
2022 - March
Eribulin Mesylate
Australia DMF
2022 - March
Molnupiravir
WHO DMF Filed
2022 - March
Fexofenadine Hydrochloride (Form-I)
Brazil DMF
2022 - February
Omeprazole Magnesium
CEP Submitted
2022 - February
Dasatinib Monohydrate
Japan DMF
2022 - February
Dapagliflozin Amorphous
Brazil DMF
2022 - January
Losartan Potassium [Form-I]
Korea DMF
2022 - January
Losartan Potassium [Form-I]
Brazil DMF
2022 - January
Losartan Potassium [Form 1]
CEP Submitted
2022 - January
Capecitabine
Japan DMF
2023 - December
Cabozantinib (S)-Malate [Form N-2]
USDMF
2023 - December
Cabozantinib Intermediate (CZT3)*
USDMF
2023 - December
Ezetimibe (EZE)
USDMF
2023 - December
Lumateperone Tosylate
Brazil DMF
2023 - December
Roxadustat
Brazil DMF
2023 - December
Pantoprazole sodium sesquihydrate (Form-I) Ph. Eur
Brazil DMF
2023 - December
Rabeprazole sodium Ph. Eur
Brazil DMF
2023 - December
Carfilzomib
Brazil DMF
2023 - December
Lenalidomide Form-A
China DMF
2023 - December
Dabigatran Etexilate Mesylate
CEP Submitted
2023 - December
Mirabegron (Alpha Form)
CEP Submitted
2023 - December
Lenvatinib Form-C
Korea DMF
2023 - December
Capecitabine
Korea DMF
2023 - December
Dasatinib Monohydrate
Korea DMF
2023 - November
Lansoprazole
China DMF
2023 - November
Ferric Carboxy Maltose
Australia DMF
2023 - November
Olaparib
Brazil DMF
2023 - November
Dapagliflozin Amorphous
Russia DMF
2023 - November
Mirabegron
Egypt DMF
2023 - October
Cabazitaxel
Egypt DMF
2023 - October
Sugammadex Sodium
Singapore DMF
2023 - October
Liraglutide
Canada DMF
2023 - October
Varenicline Tartrate
Brazil DMF
2023 - October
Ferric Carboxymaltose
EUDMF
2023 - October
Pantoprazole Sodium
EUDMF
2023 - October
Nilotinib Hydrochloride Monohydrate
Korea DMF
2023 - October
Dapagliflozin (Amorphous)
Israel DMF
2023 - October
Roxadustat Form-A
China DMF
2023 - October
Nilotinib Hydrochloride Monohydrate
Australia DMF
2023 - October
Tafamidis Meglumine
Brazil DMF
2023 - September
Fosaprepitant Dimeglumine
Brazil DMF
2023 - September
Pregabalin
Canada DMF
2023 - September
Apixaban
Australia DMF
2023 - September
Sitagliptin hydrochloride Monohydrate
Saudi Arabia
2023 - September
Azacitidine
Egypt DMF
2023 - September
Linagliptin
Saudi Arabia
2023 - September
Dapagliflozin Amorphous
EUDMF
2023 - September
Omeprazole Magnesium
USDMF
2023 - September
Fexofenadine HCl Form I
Brazil DMF
2023 - August
Varenicline Tartrate
USDMF
2023 - August
Olaparib [Form-A]
China DMF
2023 - July
Linagliptin
Australia DMF
2023 - July
Liraglutide
EUDMF
2023 - July
Gatifloxacin Anhydrous
Brazil DMF
2023 - June
Nilotinib Hydrochloride Monohydrate
CEP Submitted
2023 - June
Tofacitinib Citrate
Brazil DMF
2023 - June
Rabeprazole Sodium
Russia DMF
2023 - June
Linagliptin
Canada DMF
2023 - June
Esomeprazole Magnesium Trihydrate
China DMF
2023 - May
Sugammadex Sodium
Japan DMF
2023 - May
Midostaurin
Australia DMF
2023 - May
Ramipril
Russia DMF
2023 - May
Moxifloxacin Hydrochloride
Singapore DMF
2023 - May
Pantoprazole Sodium Sesquihydrate
CEP Submitted
2023 - April
Ciprofloxacin Hydrochloride
China DMF
2023 - April
Telmisartan
GCC DMF
2023 - April
Bortezomib
Egypt DMF
2023 - March
Fosaprepitant Dimeglumine
USDMF
2023 - March
TBA-7A / Sitagliptin N-Boc Acid
USDMF
2023 - March
Salcaprozate Sodium
USDMF
2023 - March
Cabozantinib Hydrochloride
USDMF
2023 - March
Lumateperone Tosylate
USDMF
2023 - March
Clopidogrel Bisulphate [Form-II] USP DIFA
Brazil DMF
2023 - March
Cetirizine Dihydrochloride USP
Brazil DMF
2023 - March
Fluoxetine Hydrochloride USP
Brazil DMF
2023 - March
Lenvatinib Mesylate (Form C)
Brazil DMF
2023 - March
Pioglitazone Hydrochloride USP
Brazil DMF
2023 - March
Pioglitazone Hydrochloride Ph. Eur
Brazil DMF
2023 - March
Pantoprazole Sodium Sesquihydrate
Brazil DMF
2023 - March
Levofloxacin Hemihydrate Ph.Eur
Brazil DMF
2023 - March
Pemetrexed Disodium (Heptahydrate)
CEP Submitted
2023 - March
Nilotinib Hydrochloride Monohydrate
Canada DMF
2023 - March
Dimethyl Fumarate
China DMF
2023 - March
Montelukast Sodium
China DMF
2023 - March
Voriconazole CIP
China DMF
2023 - March
Nilotinib Hydrochloride
China DMF
2023 - March
Rivastigmine
China DMF
2023 - March
Valsartan
Japan DMF
2023 - March
Abiraterone Acetate
Korea DMF
2023 - March
Naratriptan Hydrochloride
Korea DMF
2023 - March
Enzalutamide
Taiwan DMF
2023 - March
Enzalutamide
Singapore DMF
2023 - February
Esomeprazole Magnesium Trihydrate
CEP Submitted
2023 - February
Atorvastatin Calcium Trihydrate (Form-1) USP
China DMF
2023 - February
Tafamidis Meglumine
USDMF
2023 - February
Pemetrexed Disodium (Heptahydrate)
Korea DMF
2023 - February
Sumatriptan succinate
Brazil DMF
2023 - January
Sumatriptan succinate
CEP Submitted
2023 - January
Abiraterone Acetate
Brazil DMF
2023 - January
Pregabalin
Brazil DMF
2023 - January
Apalutamide Form-B
Brazil DMF
2024 - December
Quetiapine Fumarate
Japan DMF
2024 - December
Cinacalcet Hydrochloride
China DMF
2024 - December
Abemaciclib
Brazil DMF
2024 - December
Dabigatran Etexilate Mesylate (P2)
Brazil DMF
2024 - December
Sitagliptin Phosphate Monohydrate (Product code:SPT-4)
CEP Submitted
2024 - December
Abemaciclib
USDMF
2024 - December
Voclosporin
USDMF
2024 - December
Mavacamten
USDMF
2024 - November
Ketorolac Tromethamine (Parenteral)
Brazil DMF
2024 - November
Moxifloxacin Hydrochloride
Egypt DMF
2024 - November
Ferric Carboxy Maltose
Malaysia DMF
2024 - November
Atorvastatin Calcium Trihydrate (Form-1) (ATO-3 route)
Oman DMF
2024 - November
Siponimod Hemifumarate
Australia DMF
2024 - October
Benztropine Mesylate
Saudi Arabia
2024 - October
Dimethyl Fumarate
Saudi Arabia
2024 - October
Memantine Hydrochloride
Russia DMF
2024 - October
Sitagliptin Phosphate Monohydrate
USDMF
2024 - October
Cabozantinib (S)-Malate [Form N-2]
Brazil DMF
2024 - October
Sacubitril Sodium
Brazil DMF
2024 - October
Ferric Carboxy Maltose
China DMF
2024 - October
Ezetimibe
Brazil DMF
2024 - October
Sitagliptin Phosphate Monohydrate
Brazil DMF
2024 - October
Dasatinib Monohydrate
Brazil DMF
2024 - October
Dabigatran Etexilate Mesylate
USDMF
2024 - October
Empagliflozin [Product code: EGF8]
Canada DMF
2024 - October
Naproxen Sodium Ph. Eur
Brazil DMF
2024 - October
Linagliptin Form (A+B)
EUDMF
2024 - August
Sacubitril/Valsartan
Australia DMF
2024 - August
Dabigatran Etexilate Mesylate
CEP Submitted
2024 - August
Sacubitril Sodium
USDMF
2024 - July
Dasatinib Monohydrate
Australia DMF
2024 - July
Lenvatinib Mesylate Form-C
Australia DMF
2024 - July
Empagliflozin Crystalline [Micronized]
Australia DMF
2024 - June
Lanreotide
US filing
2024 - June
Mirabegron Ph. Eur
Brazil DMF
2024 - June
Dasatinib Monohydrate
Canada DMF
2024 - June
Nilotinib Hydrochloride Monohydrate
Taiwan DMF
2024 - June
Rivastigmine Hydrogen Tartrate
Taiwan DMF
2024 - June
Midostaurin Amorphous
India
2024 - June
Bempedoic Acid
India
2024 - June
Pantoprazole Sodium Sesiquihydrate
Saudi Arabia
2024 - May
Ketorolac Tromethamine
Saudi Arabia
2024 - May
Enzalutamide
Canada DMF
2024 - April
Cabazitaxel
Taiwan DMF
2024 - March
Relugolix
USDMF
2024 - March
Lenvatinib Mesylate (Form-C)
Canada DMF
2024 - March
Levocetirizine Dihydrochloride
CEP Submitted
2024 - March
Irbesartan
CEP Submitted
2024 - March
Relugolix Sodium
Brazil DMF
2024 - March
Carfilzomib
China DMF
2024 - March
Decitabine
Korea DMF
2024 - February
Edaravone
Brazil DMF
2024 - February
Ripretinib
USDMF
2024 - February
Ripretinib
Brazil DMF
2024 - February
Vonoprazan Fumarate
USDMF
2024 - February
Vonoprazan Fumarate
Brazil DMF
2024 - February
Ondansetron
Canada DMF
2024 - February
Dabigatran Etexilate Mesylate
Russia DMF
2024 - February
Permethrin BPC cis trans 25 75
Korea DMF
2024 - February
Lomustine
China DMF
2024 - February
Pantoprazole Sodium Sesiquihydrate
China DMF
2024 - February
Donepezil Hydrochloride Monohydrate (Form-1)
CEP Submitted
2024 - January
Lenalidomide Form-A
Japan DMF
2024 - January
Linagliptin Form A+B
Brazil DMF
2025 - July
Edoxaban Tosylate
USDMF
2025 - July
Voriconazole
Russia DMF
2025 - July
Relugolix
India
2025 - July
Liraglutide
Saudi Arabia
2025 - July
Permethrin
Saudi Arabia
2025 - June
Docetaxel Anhydrous
Kenya
2025 - June
Palonosetron Hydrochloride USP
Ethiopia
2025 - June
Cabazitaxel
Kenya
2025 - June
Tucatinib Hemiethanolate
Brazil DMF
2025 - June
Finerenone
Brazil DMF
2025 - May
Dapagliflozin Amorphous
Switzerland
2025 - May
Nilotinib Hydrochloride Monohydrate
Indonesia
2025 - April
Bempedoic acid
Russia DMF
2025 - March
Montelukast Sodium
Japan DMF
2025 - March
Apixaban
Taiwan DMF
2025 - March
Palbociclib
Canada DMF
2025 - March
Deucravacitinib
USDMF
2025 - March
Finerenone
USDMF
2025 - March
Niraparib Tosylate Monohydrate
USDMF
2025 - March
Tucatinib
USDMF
2025 - March
Voclosporin
Brazil DMF
2025 - March
Lanreotide
Brazil DMF
2025 - March
Pomalidomide
2025 - March
Vonoprazan Fumarate
Korea DMF
2025 - March
Palbociclib
Korea DMF
2025 - March
Ezetimibe (Unmicronized)
Korea DMF
2025 - March
Mavacamten Form-A
Brazil DMF
2025 - March
Fexofenadine HCl (Form-1) -FXA4 process
CEP Submitted
2025 - March
Amlodipine Besylate (TY45)
CEP Submitted
2025 - March
Tucatinib Hemiethanolate
USDMF
2025 - March
Tizanidine Hydrochloride USP (TZN-Process)
USDMF
2025 - March
Enzalutamide Premix (20% w/w)
USDMF
2025 - March
Pazopanib HCl
EUDMF
2025 - March
Atorvastatin Calcium Trihydrate form-1 [ATO-3 process]
CEP Submitted
2025 - March
Ezetimibe (Micronized)
Korea DMF
2025 - February
Montelukast Sodium
Japan DMF
2025 - February
Pioglitazone Hydrochloride
Canada DMF
2025 - February
Cabozantinib S- Maleate (N2 Form)
Korea DMF
2025 - February
Palbociclib
Singapore DMF
2025 - February
Ferric Carboxy Maltose
Saudi Arabia
2025 - January
Fexofenadine Form I
Brazil DMF
2025 - January
Sacubitril/ Valsartan
Canada DMF
2025 - January
Dasatinib Monohydrate
Taiwan DMF
2025 - January
Pazopanib
Taiwan DMF
免责声明
本網站上的任何信息，包括對任何產品或服務的任何提及，均不構成銷售要約或被解釋為代表銷售要約。受有效專利保護的產品不得提供或供應用於商業用途。但是，在某些情況下，雷迪博士可自行決定並根據當地法律要求，在存在此類監管豁免的任何地方，提供此類產品的研究數量，以根據《印度專利法》第 107A 條（Bolar 豁免）進行監管提交。購買者應對其各自市場的產品或服務（包括專利情況）進行獨立評估，並對所有與專利相關的責任負責。 Dr. Reddy's 不承擔任何明示或暗示的保證，包括但不限於適銷性、適用於特定用途和非侵權的保證。